After participating in the iwCLL, learners should be better able to evaluate and interpret the clinical significance of emerging evidence regarding:
• factors that contribute to the development of CLL
• the diagnosis, prognosis, and initial treatment of CLL
• factors that contribute to disease evolution and progression
• treatment of advanced disease
Hematologists/oncologists who treat patients with CLL and researchers, oncology nurses, and pharmacists, and other clinicians and researchers with an interest in the biology, diagnosis, and treatment of CLL
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, and Bio Ascend and iwCLL. The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 16.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by educational grants from Acerta Pharma – A member of the AstraZeneca Group,, Celgene Corporation, and Genentech, Inc.
Disclosure of relationships with commercial interests
As a provider accredited by the ACCME, The University of Nebraska Medical Center, Center for Continuing Education requires that CME-certified activities be balanced, independent, objective, and scientifically rigorous. All persons involved in planning, developing, or approving content for this activity must disclose all financial relationships with pharmaceutical and biotechnology companies, biomedical device manufacturers and distributors, and other for-profit organizations whose products or services relate to the content of the activity. Any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients is defined by the ACCME as a commercial interest (CI). The University of Nebraska Medical Center, Center for Continuing Education has taken steps to resolve all conflicts of interest.
Discussion of investigational and off-label usage
The faculty may discuss unlabeled uses of Food and Drug Administration (FDA)-approved products and investigational uses of approved and emerging agents. Use of any product should be undertaken only after consulting FDA-approved labelling and primary references.
Faculty for this activity have been asked to provide complete, accurate, relevant content based on best-available evidence. The opinions expressed during this activity are those of the faculty and do not reflect those of The University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend.
Participants have a responsibility to use newly acquired information to improve their practice and their own professional development. Clinician-learners are encouraged to reflect on their patients and their practice and determine how best to apply knowledge and skills gained from this activity.
The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
Please contact us at firstname.lastname@example.org for more information.